Cardiovascular risk in Cushing's syndrome

被引：67

作者：

Arnaldi G. ^{[1
]}

Mancini T. ^{[1
,2
]}

Polenta B. ^{[1
]}

Boscaro M. ^{[1
]}

机构：

[1] Division of Endocrinology, Polytechnic University of the Marche Region, 60020 Ancona, Via Conca

[2] Division of Medicine, San Marino Hospital, Ancona

来源：

Pituitary | 2004年 / 7卷 / 4期

关键词：

Cardiovascular risk; Cushing's syndrome; Diabetes mellitus; Hypercortisolism; Hypertension; Obesity;

D O I：

10.1007/s11102-005-1172-7

中图分类号：

学科分类号：

摘要：

Chronic cortisol hypersecretion causes central obesity, hypertension, insulin resistance, dyslipidemia, protrombotic state, manifestations which form a metabolic syndrome in all patients with Cushing's syndrome. These associated abnormalities determine an increased cardiovascular risk not only during the active phase of the disease but also long after the "biomedical remission". Clinical management of these patients should be particularly careful in identifyin global cardiovascular risk. Considering that remission from hypercortisolism is often difficult to achieve care and controlof all cardiovascular risk factors should be one of the primary goals during the follow up of these patients. Extending the indications of the recent consensus on Cushing's syndrome, we suggest to carry out an OGTT to avoid underestimation of diabetes mellitus, an echocardiography and Doppler ultrasonography of the epiaortic vessels in all patients at diagnosisand during follow-up. © Springer Science + Business Media, Inc. 2005.

引用

页码：253 / 256

页数：3

共 19 条

[1] Arnaldi G., Angeli A., Atkinson A.B., Bertagna X., Cavagnini F., Chrousos G., Fava G.A., Findling J., Gaillard R.C., Grossman A.B., Kola B., Lacroix A., Mancini T., Mantero F., Newell-Price J., Nieman L.K., Sonino N., Vance M.L., Giustina A., Boscaro M., Diagnosis and complications of Cushing's syndrome: A consensus statement, J Clin Endocrinal Metab, 88, pp. 5593-5602, (2003)
[2] Colao A., Pivonello R., Spiezia S., Faggiano A., Ferone D., Filippella M., Marzullo P., Cerbone G., Siciliani M., Lombardi G., Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure, J Clin Endocrinal Metab, 84, pp. 2664-2672, (1999)
[3] Etxabe J., Vazquez J.A., Morbidity and mortality in Cushing's disease: An epidemiological approach, Clin Endocrinal, 23, pp. 479-480, (1994)
[4] Andrews R.C., Walker B.R., Glucocorticoids and insulin resistance: Old hormones, new targets, Clin Sci, 96, pp. 513-523, (1999)
[5] Danese R.D., Aron D.C., Cushing's syndrome and hypertension, Endocrinal Metab Clin of North America, 23, pp. 223-299, (1994)
[6] Giraldi F.P., Moro M., Cavagnini F., Study group on the hypothalamo-pituitary-adrenal axis of the Italian society of endocrinology. Gender-related differences in the presentation and course of Cushing's disease, J Clin Endocr Metab, 88, pp. 1554-1558, (2003)
[7] Mancini T., Kola B., Concettoni C., Boscaro M., Mantero F., Arnaldi G., Hypertension in patients with Cushing's syndrome: Evidence for gender difference in 11β hydroxysteroid dehydrogenase type 2 activity, The Endocrine Society 85nd Annual Meeting, (2003)
[8] Magiakou M.A., Mastrokaros G., Olfield E.A., Gomez M.T., Doppman J.L., Cutler G.B.J., Nieman L.K., Chrousos GPCushing's syndrome in children and adolescents: Presentation, diagnosis and therapy, New England J Med, 331, pp. 629-636, (1994)
[9] Biglieri E.G., Kater C.E., Mantero F., Adrenocortical forms of human hypertension, Hypertension, (1995)
[10] Sala C., Ambrosi B., Morganti A., Blunted vascular and renal effects of exogenous atrial natriuretic peptide in patients with Cushing's disease, J Clin Endocrinol Metab, 86, pp. 1957-1961, (2001)

← 1 2 →